AbbVie Bid for Biotech Could Expand with Experimental Drug
AbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
Explore zero based budgeting tips tailored for large families, focusing on scalable expense categorization and practical saving methods.
23,089 articlesAbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
June markets test XLE as oil dynamics and earnings timing hedges collide. A handful of energy giants drive the ETF, u...
Defensive investing can pay off when markets wobble. This article compares two staples-focused ETFs—iShares U.S. Cons...
Investors are pouring capital into a new class of AI startups focused on world models, a movement led by tech founder...
SharpLink Gaming resumes ETH purchases after eight months, fueling a renewed ethereum price prediction: forgotten con...
After years of setbacks, Intel appears to be turning a corner on its AI ambitions. This article breaks down what to w...
As U.S. AI export controls tighten, investors face a push-pull: tighter access could spur China’s open-source AI ecos...
A major market moment is shaping up as Dan Ives weighs in on SpaceX’s potential public debut. This article breaks dow...
First MLS appoints Jenni Bonura as Chief Growth Officer, signaling a bold expansion push across Georgia and the South...
FEPI’s high yield relies on aggressive call-writing against a tech-heavy basket. While payouts appear robust, scrutin...
The spotlight in AI investing is shifting from screens to factories. The BOTZ ETF is positioning itself to ride a wav...
Micron Technology now carries roughly double the weight of Meta Platforms in QQQ, driven by free-float rules that tri...